Former Legend Biotech CEO Ying Huang appointed head of K2 Therapeutics as startup secures $50M seed funding

Ying Huang, who led Legend Biotech for seven years and helped develop a top‑selling cell therapy for multiple myeloma, has been named chief executive of K2 Therapeutics.

The young company, founded by investor MPM BioImpact in 2024, announced a $50 million seed financing round to fund its plan to in‑license and develop high‑potential drug candidates.

K2 already holds eight programs ranging from preclinical to early clinical stages, including an antibody‑drug conjugate and a T‑cell engager acquired through recent deals with Chinese firms Adcoris and Antengene, with an option on a third undisclosed candidate.